EARNEST Partners’s BeOne Medicines Ltd ONC Stock Holding History

EARNEST Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7	Closed	-$3K	–	1209
2021 Q3	$3K	Hold	7	–	–	﹤0.01%	989
2021 Q2	$2K	Hold	7	–	–	﹤0.01%	1072
2021 Q1	$2K	Hold	7	–	–	﹤0.01%	1078
2020 Q4	$2K	Hold	7	–	–	﹤0.01%	1057
2020 Q3	$2K	Hold	7	–	–	﹤0.01%	1005
2020 Q2	$1K	Buy	+7	New	+$1.14K	﹤0.01%	1113

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

EARNEST Partners's ONC Position: Q4 2021 in Review

EARNEST Partners sold out of BeOne Medicines Ltd (ONC) in Q4 2021, closing a stake of 7 shares — an estimated $3K sold.

EARNEST Partners first reported a position in ONC in Q2 2020 and held it in 6 quarters. The position peaked at $3K in Q3 2021. 263 funds tracked by Wall St. Rank hold ONC as of Q4 2021.

EARNEST Partners reported no remaining BeOne Medicines Ltd position as of Q4 2021 after selling out during the quarter.
EARNEST Partners sold 7 BeOne Medicines Ltd shares in Q4 2021, an estimated $3K.
EARNEST Partners first reported a position in BeOne Medicines Ltd in Q2 2020 and held it in 6 quarters.
EARNEST Partners's BeOne Medicines Ltd position peaked at $3K in Q3 2021.
263 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2021.

Based on EARNEST Partners's 13F filing for Q4 2021, filed 7 Feb 2022.